Bristol Myers Squibb (BMY) Total Debt (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Total Debt for 18 consecutive years, with $43.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt fell 18.21% year-over-year to $43.9 billion in Q2 2026; TTM through Jun 2026 was $43.9 billion, a 18.21% decrease from a year earlier, with the FY2025 full-year figure at $47.1 billion, down 8.53% from the prior year.
• Total Debt was $43.9 billion for Q2 2026 at Bristol Myers Squibb, down from $46.4 billion in the prior quarter.
• Over five years, Total Debt peaked at $58.6 billion in Q1 2024 and troughed at $40.1 billion in Q1 2023.
• A 5-year average of $47.9 billion and a median of $46.9 billion in 2022 frame the typical range for Total Debt.
• Across the five-year window, Total Debt fell 23.31% in 2023 and jumped 46.07% in 2024, its largest moves.
• Over 5 years, Total Debt stood at $43.2 billion in 2022, then declined by 1.32% to $42.6 billion in 2023, then grew by 20.71% to $51.5 billion in 2024, then retreated by 8.53% to $47.1 billion in 2025, then fell by 6.8% to $43.9 billion in 2026.
• The last three Total Debt figures came in at $43.9 billion (Q2 2026), $46.4 billion (Q1 2026), and $47.1 billion (Q4 2025), per Business Quant data.